Suppliers / Amgen

Amgen

United States AMGN 6 duplicate records merged Updated 9 July 2026

Amgen is a finished-dose manufacturer based in United States. It appears in 1,081 regulatory filings across 36 regulators, without an active US DMF or CEP on file. Its filings concentrate with Health Canada, INFARMED (PT) and US FDA. Its GMP standing is certified by EMA, US FDA and HSA (SG), among 8 authorities. Its most recent recorded inspection, by US FDA, closed on 6 November 2025 as NAI.

0
active US DMFs
0
valid CEPs
12
registered plants 1 with an FDA FEI number
1,081
filings across 36 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
4 of 8 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 6 November 2025 NAI US FDA
  • 7 August 2025 NAI US FDA
  • 13 March 2025 VAI US FDA
  • 4 February 2025 NAI US FDA
  • 30 July 2024 NAI US FDA
  • 14 September 2023 NAI US FDA
  • 13 September 2023 NAI US FDA
  • 28 July 2023 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Breda, United Arab Emirates Not on file
Thousan Oaks, United Arab Emirates Not on file
Juncos, United Arab Emirates Not on file
Dublin, United Arab Emirates Not on file
Dublin, United Arab Emirates Not on file
Risch, Switzerland Not on file

6 further sites are on record.

Filings and GMP by regulator

Regulator Filings GMP certificates
Health Canada 308 None
INFARMED (PT) 86 None
US FDA 81 5
ANSM (FR) 71 None
SWISSMEDIC (CH) 64 None
MHRA (UK) 47 1
EMA None 6
HSA (SG) None 5
EAEU_EEC None 4
ANVISA (Brazil) None 4
NCELS (KZ) None 1
NAFDAC (NG) None 1

Scale

Year Revenue Exports Destinations
2020 $25.4B Not reported Not reported
2019 $23.4B Not reported Not reported
2018 $23.7B Not reported Not reported

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. Amgen comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 6 November 2025.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Company filings
Revenue as reported